USA flag logo/image

An Official Website of the United States Government

Nanocomposite Imaging System for the Eye

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43EY021438
Solicitation Year:
2011
Solicitation Topic Code:
NEI
Solicitation Number:
PA10-050
Small Business Information
Kypha, Inc.
4320 Forest Park Ave STE. 303 SAINT LOUIS, MO 63108
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Nanocomposite Imaging System for the Eye
Agency: HHS
Contract: 1R43EY021438-01
Award Amount: $273,487.00
 

Abstract:

DESCRIPTION (provided by applicant): The purpose of this SBIR project is to develop a new dual-modality inflammation imaging technology to early detect Uveitis, an ocular inflammation-related disorder. This technology, based on nanocomposites (NCs) that function as dual-modality fluorescent and acoustic contrast agents for optical and ultrasound imaging techniques, will allow both quantitative and whole-eye inflammation monitoring. In addition, the contrast-enhanced ultrasound (CEUS) modality means theNCs can be monitored using equipment present in most retinal specialists' offices. In United States, Uveitis affects 350,000 persons and is the fourth leading cause of blindness responsible for 30,000 new cases each year. The loss of vision is correlated with the severity, recurrence and duration of inflammatory episodes. Hence, early detection and continued control of the disease are critical. For treating uveitis, it is desirable to have a method that can quantitatively measure the extent of inflammationin the entire eye. This would aid in both assessing the extent of inflammation in monitoring the patients response to treatment. Current methods for monitoring ocular inflammation lack either the ability to (i) assess the whole eye or (ii) not quantitative. At present, no single technology can provide both quantitative and whole- eye monitoring of Uveitis-related inflammation. The new concurrent optical and ultrasound imaging that we propose will quickly, quantitatively and non- invasively assess inflammation in the entire eye. The first aim is to produce acoustically and fluorescently active NCs. In order to precisely locate and quantify ocular inflammation and allow more accurate monitoring of the patient response to Uveitis treatment, NCs will be decorated with ligands that target key biomarkers up- regulated on activated vascular endothelial cells. This strategy will not only improve diagnosis of inflammation, but also the degree of inflammation. The successful completion of this technology would producea paradigm-shifting advance in how retinal specialists will easily and rapidly diagnose Uveitis while simultaneously monitoring the location and extent of the associated ocular inflammation. Specialists will be able to implement a therapeutic strategy early and then monitor and adjust over time as fluctuations in inflammation and potential side-effects present, thus preventing vision impairments. PUBLIC HEALTH RELEVANCE: The aim of the proposal is to develop a new dual-modality inflammation imaging technology to early detect uveitis, an ocular inflammation-related disorder. Uveitis affects 350,000 persons and is the fourth leading cause of blindness responsible for 30,000 new cases each year. The successful completion of this technology would produce a paradigm-shifting advance in how retinal specialists will easily and rapidly diagnose uveitis while simultaneously monitoring the location and extent of the associated ocular inflammation, thus allowing them to implement an optimal therapy.

Principal Investigator:

Paul K. Olson
502-569-1075
paul@ky-pha.com

Business Contact:

Paul K. Olson
502-569-1075
paul@ky-pha.com
Small Business Information at Submission:

KENTUCKY PHARMACEUTICALS, INC.
4320 Forest Park Ave STE. 303 SAINT LOUIS, MO 63108

EIN/Tax ID: 127100957
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No